BridgeBio Pharma, Inc. (BBIO) Total Return Calculator with Dividends Reinvested

BridgeBio Pharma, Inc.

Popular:

The total return for BridgeBio Pharma, Inc. (BBIO) stock is +65.67% over the past 12 months. So far it's down 15.29% this year. The 5-year total return is +8.05%, meaning $10,000 invested in BBIO stock 5 years ago would be worth $10,805 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in BBIO 1 year ago, it would be worth $15,711 today — you'd have gained $5,711.

With Dividends Reinvested$15,711+57.11%

Price Only (No DRIP)$15,711+57.11%

Period2025-06-23 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in BBIO

1Y$16,568+$6,568 (+65.7%)65.7% CAGR

3Y$40,115+$30,115 (+301.2%)58.9% CAGR

5Y$10,805+$805 (+8.1%)1.6% CAGR

10Y$24,054+$14,054 (+140.5%)9.2% CAGR

15Y$24,055+$14,055 (+140.5%)6.0% CAGR

20Y$24,054+$14,054 (+140.5%)4.5% CAGR

30Y$24,054+$14,054 (+140.5%)3.0% CAGR

BridgeBio Pharma, Inc. did not pay dividends during this period. Total return = price return.

Loading BBIO total return...

As of 2026-06-22

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-15.29%	—	-15.29%	—	$8,471
1Y	+65.67%	65.67%	+65.67%	—	$16,568
3Y	+301.15%	58.89%	+301.15%	—	$40,115
5Y	+8.05%	1.56%	+8.05%	—	$10,805
10Y	+140.54%	9.17%	+140.54%	—	$24,054
15Y	+140.55%	6.03%	+140.55%	—	$24,055
20Y	+140.54%	4.49%	+140.54%	—	$24,054
30Y	+140.54%	2.97%	+140.54%	—	$24,054

Risk & Highlights

Best Year+463.04%2023

Worst Year-73.79%2021

Max Drawdown-20.25%2026-01-22 → 2026-02-05

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-15.03%	-15.03%	—	+0.41%	-15.4pp
2025	+171.24%	+171.24%	—	+16.64%	+154.6pp
2024	-32.16%	-32.16%	—	+24.00%	-56.2pp
2023	+463.04%	+463.04%	—	+24.81%	+438.2pp
2022	-55.59%	-55.59%	—	-19.95%	-35.6pp

BBIO outperformed the S&P 500 by 40.69pp over the past year (+65.67% vs +24.99%).

Loading summary...

BBIO Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
BBIOBridgeBio Pharma, Inc.	$13.0B	+1.5%	-15.3%	+65.7%	—	+301.2%	+8.1%	+140.5%
KYMRKymera Therapeutics, Inc.	$7.4B	+13.5%	+24.3%	+94.7%	—	+259.0%	+91.0%	+171.9%
ARRYArray Technologies, Inc.	$1.2B	-5.3%	-17.4%	+6.1%	—	-62.5%	-50.6%	-78.1%
RCUSArcus Biosciences, Inc.	$2.4B	+3.9%	+4.4%	+185.7%	—	+28.3%	+5.4%	+43.0%
PRAXPraxis Precision Medicines, Inc.	$8.2B	-11.9%	-1.4%	+557.0%	—	+1611.0%	-12.5%	-32.3%
VRTXVertex Pharmaceuticals Incorporated	$114.9B	+3.4%	-0.1%	+0.7%	—	+31.8%	+140.4%	+420.8%
ACADACADIA Pharmaceuticals Inc.	$3.7B	+4.5%	-17.3%	-5.8%	—	-9.3%	-16.9%	-42.2%
RAREUltragenyx Pharmaceutical Inc.	$2.7B	+13.4%	+16.3%	-26.5%	—	-45.3%	-71.1%	-49.7%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
BEAMBeam Therapeutics Inc.	$3.5B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
EDITEditas Medicine, Inc.	$263M	+6.3%	+31.2%	+14.5%	—	-67.8%	-92.5%	-90.9%

Compare:BBIO vs KYMR BBIO vs ARRY BBIO vs RCUS BBIO vs KYMR vs ARRY

About BBIO Dividend Returns

BridgeBio Pharma, Inc. (BBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of BBIO over the past year?

BridgeBio Pharma, Inc. (BBIO) delivered a return of 65.67% over the past year. Since BBIO does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in BBIO be worth today?

A $10,000 investment in BridgeBio Pharma, Inc. one year ago would be worth $16,568 today, representing a gain of $6,568.

Q3Does BBIO pay dividends?

BridgeBio Pharma, Inc. (BBIO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BBIO, the total return equals the price-only return.

Q4Did BBIO beat the S&P 500?

Yes, BridgeBio Pharma, Inc. (BBIO) outperformed the S&P 500 by 40.69 percentage points over the past year. BBIO delivered a total return of 65.67%, compared to the S&P 500's 24.99%. This 40.69pp alpha means investors in BBIO earned more than a passive S&P 500 index fund.

Q5What is BBIO's worst drawdown?

BridgeBio Pharma, Inc. (BBIO) experienced a maximum drawdown of -20.25% over the past year, declining from its peak on 2026-01-22 to its trough on 2026-02-05. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is BBIO's long-term total return over 10, 20, or 30 years?

Here are BridgeBio Pharma, Inc. (BBIO)'s long-term returns with dividends reinvested. Over 10 years, the total return is 140.5% (9.2% CAGR) — $10,000 would have grown to $24,054. Over 20 years: 140.5% total return (4.5% CAGR) — $10,000 → $24,054. Over 30 years: 140.5% total return (3.0% CAGR) — $10,000 → $24,054. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was BBIO's best and worst year?

BridgeBio Pharma, Inc.'s best calendar year was 2023 with a total return of 463.0%. Its worst year was 2021 with a total return of -73.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 536.8 percentage points.

How much would $100/month in BBIO be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →